Department of Surgery, Emory University School of Medicine, Atlanta, GA, United States; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States; Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States.
Department of Surgery, Emory University School of Medicine, Atlanta, GA, United States; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
Diabetes Res Clin Pract. 2023 Jan;195:110202. doi: 10.1016/j.diabres.2022.110202. Epub 2022 Dec 7.
Some evidence suggests that diabetes may be a risk factor for the development of post-acute sequelae of COVID-19 (PASC). Recent data also indicate that new-onset diabetes may be a complication of COVID-19. Here, we review the existing evidence. Following PRISMA guidelines, we conducted a systematic review through August 8, 2022. We included longitudinal studies reporting on the risk of PASC (i.e., sequelae that extend beyond four weeks after initial infection) in people with and without diabetes, and studies reporting on the risk of new-onset diabetes in people with vs without COVID-19 with a minimum of 4-weeks of follow-up. All studies were published in English. Among 5,532 studies screened, 39 were included in the final review. Among 25 studies reporting on diabetes and PASC, 44 % (n = 11) identified diabetes as a significant risk factor for PASC (increased relative risk ranging from 7 % to 342 %) while 56 % (n = 14) did not. Among 14 studies reporting on new-onset diabetes, 12 (86 %) reported that COVID-19 (vs no COVID) was significantly associated with new-onset diabetes with increased risks ranging from 11 % to 276 %. COVID-19 survivors may be at increased risk for new-onset diabetes, but whether pre-existing diabetes is also a risk factor for PASC remains unclear.
一些证据表明,糖尿病可能是 COVID-19 后急性后遗症 (PASC) 发展的一个风险因素。最近的数据也表明,新发糖尿病可能是 COVID-19 的一种并发症。在这里,我们回顾了现有证据。根据 PRISMA 指南,我们进行了系统评价,截止到 2022 年 8 月 8 日。我们纳入了报告糖尿病患者(即初始感染后超过四周的后遗症)与无糖尿病患者发生 PASC 风险的纵向研究,以及报告 COVID-19 患者与无 COVID-19 患者新发糖尿病风险的研究,随访时间至少为 4 周。所有研究均以英文发表。在筛选出的 5532 项研究中,有 39 项研究纳入最终综述。在报告糖尿病和 PASC 的 25 项研究中,44%(n=11)确定糖尿病是 PASC 的一个显著危险因素(增加的相对风险范围为 7%至 342%),而 56%(n=14)没有。在报告新发糖尿病的 14 项研究中,有 12 项(86%)报告 COVID-19(与无 COVID 相比)与新发糖尿病显著相关,风险增加范围为 11%至 276%。COVID-19 幸存者可能有新发糖尿病的风险增加,但既往糖尿病是否也是 PASC 的一个危险因素仍不清楚。